These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 7981019)

  • 1. Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).
    Br J Clin Pharmacol; 1994 Aug; 38(2):95-7. PubMed ID: 7981019
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines.
    Ayres JG; Frost CD; Holmes WF; Williams DR; Ward SM
    BMJ; 1998 Oct; 317(7163):926-30. PubMed ID: 9756813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed.
    Waller PC; Wood SM; Breckenridge AM; Rawlins MD
    Br J Clin Pharmacol; 1994 Aug; 38(2):93. PubMed ID: 7981018
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of company postmarketing surveillance studies.
    Waller PC; Wood SM; Langman MJ; Breckenridge AM; Rawlins MD
    BMJ; 1992 Jun; 304(6840):1470-2. PubMed ID: 1611368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New horizons in post-marketing surveillance.
    Waller P; Wood S
    Health Trends; 1993; 25(3):83. PubMed ID: 10131867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recalls. FDA, industry cooperate to protect consumers.
    Nordenberg T
    FDA Consum; 1995 Oct; 29(8):24-7. PubMed ID: 10151838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Code of practice for the clinical assessment of licensed medicinal products in general practice.
    Br Med J (Clin Res Ed); 1983 Apr; 286(6373):1295-7. PubMed ID: 6404435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug regulation in the United Kingdom.
    Dollery CT
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 2):689-93. PubMed ID: 1269209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The compensation of patients injured in clinical trials.
    Barton JM; Macmillan MS; Sawyer L
    J Med Ethics; 1995 Jun; 21(3):166-9. PubMed ID: 7674282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food and drugs: why different approaches to their safety?
    Turner P
    Lancet; 1984 May; 1(8386):1116. PubMed ID: 6144841
    [No Abstract]   [Full Text] [Related]  

  • 11. The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.
    Forbes AL
    Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 2):S20-1; discussion S31-7. PubMed ID: 8801611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informed consent to postmarketing research. British rules outlaw disguised promotion of drugs.
    Wells F
    BMJ; 1995 Sep; 311(7006):692. PubMed ID: 7549671
    [No Abstract]   [Full Text] [Related]  

  • 14. [Importing medicines with quality assurance].
    Agência Nacional de Vigilância Sanitária - Anvisa
    Rev Saude Publica; 2004 Apr; 38(2):337-8. PubMed ID: 15122397
    [No Abstract]   [Full Text] [Related]  

  • 15. European drug regulation--anti-protectionism or consumer protection?
    Lancet; 1991 Jun; 337(8757):1571-2. PubMed ID: 1675711
    [No Abstract]   [Full Text] [Related]  

  • 16. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New consumer guidance on herbal medicines.
    Kerr C
    Lancet Oncol; 2006 Sep; 7(9):714. PubMed ID: 16977733
    [No Abstract]   [Full Text] [Related]  

  • 18. Promotion of medicines.
    Massam D
    Lancet; 1989 Jun; 1(8650):1330. PubMed ID: 2566856
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the US submisson process.
    Donawa M
    Med Device Technol; 2004 Apr; 15(3):30-2. PubMed ID: 15255536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.